Lyvispah (Baclofen) Patent Expiration, LOE Window & CMS Spending
Lyvispah (Baclofen) by Strides International Ag: FDA Orange Book LOE 2041-09-29, 19 AB generics, $369K 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Strides International Ag |
| FDA Application & Pathway | N215422 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2041-09-29 |
| Orange Book Patents (*PED Extensions) | 5 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 19 |
| 2024 CMS Total Public Spend | $369K |
| 2024 Medicare Part D Spend | $163K |
| 2024 Medicaid Spend | $206K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |